2 results
Approved WMOWill not start
Primary objective:* To demonstrate that subjects who receive an 8-day series of Otelixizumab infusions have greater improvement than subjects who receive placebo in endogenous insulin secretion at 12 months after study drug administration. Secondary…
Approved WMOPending
To assess the efficacy of inhaled RVT-1601 in comparison with placebo following 12 weeks of treatment